Literature DB >> 17300858

Sustained measles elimination in Australia and priorities for long term maintenance.

Heather F Gidding1, James Wood, C Raina MacIntyre, Heath Kelly, Stephen B Lambert, Gwendolyn L Gilbert, Peter B McIntyre.   

Abstract

We used the 2002 national serosurvey to evaluate a primary care-based young adult vaccination campaign, measure the reproductive number (R) and, together with vaccination coverage estimates, predict R until 2012. The campaign had no impact on immunity in young adults. R was estimated to be 0.69 and predicted to stay well below the epidemic threshold of 1 until at least 2012, indicating that Australia should remain free of endemic measles in the medium term. To maintain elimination in the longer term, the timeliness and coverage of childhood vaccinations must improve and innovative strategies will be required to improve measles immunity among young adults. This experience is likely to apply to developed countries that have achieved or are approaching measles elimination.

Mesh:

Substances:

Year:  2007        PMID: 17300858     DOI: 10.1016/j.vaccine.2007.01.090

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  An assessment of measles vaccine effectiveness, Australia, 2006-2012.

Authors:  Alexis Pillsbury; Helen Quinn
Journal:  Western Pac Surveill Response J       Date:  2015-07-09

2.  Elimination of endemic measles transmission in Australia.

Authors:  Anita E Heywood; Heather F Gidding; Michaela A Riddell; Peter B McIntyre; C Raina MacIntyre; Heath A Kelly
Journal:  Bull World Health Organ       Date:  2009-01       Impact factor: 9.408

3.  Contact tracing of in-flight measles exposures: lessons from an outbreak investigation and case series, Australia, 2010.

Authors:  Frank Beard; Lucinda Franklin; Steven Donohue; Rodney Moran; Stephen Lambert; Marion Maloney; Jan Humphreys; Jessica Rotty; Nicolee Martin; Michael Lyon; Thomas Tran; Christine Selvey
Journal:  Western Pac Surveill Response J       Date:  2011-08-25

4.  Using the two-source capture-recapture method to estimate the incidence and case ascertainment of congenital rubella syndrome in Australia, 1993-2013.

Authors:  Nicolee Martin; David Durrheim; Gulam Khandaker; Michelle Butler; Cheryl Jones
Journal:  Western Pac Surveill Response J       Date:  2016-03-29

5.  Estimating the measles effective reproduction number in Australia from routine notification data.

Authors:  May Chiew; Heather F Gidding; Aditi Dey; James Wood; Nicolee Martin; Stephanie Davis; Peter McIntyre
Journal:  Bull World Health Organ       Date:  2013-12-09       Impact factor: 9.408

6.  Vaccination coverage and sociodemographic determinants of measles-mumps-rubella vaccination in three different age groups.

Authors:  Corinne Vandermeulen; Mathieu Roelants; Heidi Theeten; Pierre Van Damme; Karel Hoppenbrouwers
Journal:  Eur J Pediatr       Date:  2008-01-17       Impact factor: 3.183

Review 7.  Passive immunization for the public health control of communicable diseases: current status in four high-income countries and where to next.

Authors:  Megan K Young; Allan W Cripps
Journal:  Hum Vaccin Immunother       Date:  2013-06-19       Impact factor: 3.452

8.  Current status of measles in the Republic of Korea: an overview of case-based and seroepidemiological surveillance scheme.

Authors:  Young June Choe; Geun-Ryang Bae
Journal:  Korean J Pediatr       Date:  2012-12-20

9.  Gender inequity and age-appropriate immunization coverage in India from 1992 to 2006.

Authors:  Daniel J Corsi; Diego G Bassani; Rajesh Kumar; Shally Awasthi; Raju Jotkar; Navkiran Kaur; Prabhat Jha
Journal:  BMC Int Health Hum Rights       Date:  2009-10-14

10.  Residual susceptibility to measles among young adults in Victoria, Australia following a national targeted measles-mumps-rubella vaccination campaign.

Authors:  Heath A Kelly; Heather F Gidding; Theo Karapanagiotidis; Jennie A Leydon; Michaela A Riddell
Journal:  BMC Public Health       Date:  2007-06-08       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.